REDWOOD CITY, Calif., Oct 02, 2013 (BUSINESS WIRE) --Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, today announced that it
has been named as a finalist for the CPhI Pharma Awards in the “Best
Innovation in Process Development” category. The award ceremony will
take place on October 22, 2013 in Frankfurt, Germany as part of the
annual CPhI Worldwide exhibition, which is expected to attract around
30,000 visitors from the pharmaceutical industry.
Codexis has been selected as a finalist following its development of the
first industrially-viable biocatalysts for sulfide oxidation and
Baeyer-Villiger type monooxygenations (BVMO enzymes). These optimized
enzymes can be used for improved methods to manufacture chiral
sulfoxides, which are important molecules for the pharmaceutical
industry. Codexis has used these new enzymes to develop innovative
biocatalytic processes for the production of esomeprazole and
armodafinil that overcome the shortcomings of traditional manufacturing,
including the ability to provide consistently high enantiometric purity
and minimal sulfone impurity. The enzyme and API manufacturing processes
are currently being scaled up for commercial supply.
“We are very pleased to be named a finalist for the CPhI 2013 Pharma
Awards,” said John Nicols, President and CEO of Codexis. “Biocatalysis
can offer faster, more efficient, cost-effective and greener
manufacturing routes for many pharmaceutical products and we look
forward to presenting our sulfide oxidation and BVMO enzyme technologies
to the final judging panel at CPhI in Frankfurt during this
well-respected industry event.”
Codexis’ BVMO enzymes are now commercially available as a screening kit
that process chemists can use to explore new biocatalytic oxidation
processes, which can then be readily scaled up as needed.
Codexis will be exhibiting in Hall 3.1, Booth A53 at the CPhI Worldwide
About Codexis, Inc.
Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and
implementation of biocatalytic solutions to meet customer needs for
rapid, cost-effective and sustainable process development – from
research to manufacturing. For more information, see www.codexis.com.
SOURCE: Codexis, Inc.
Paul Cox, 212-362-1200
Connor, +44 161 359 3255